(3) Parmita Mishra on X: "Precigenetics turns living biology into computable data." / X https://t.co/vXFKWrGuuv
— Paramendra Kumar Bhagat (@paramendra) March 25, 2026
but i started today with this. LOL. pic.twitter.com/FzX06IDcIx
— Parmita Mishra (@parmita) March 25, 2026
You should also go in the other direction. Write an X article. And write a book. Can hire me as a ghostwriter. And launch a web show. 30 minutes of video per day/week. Well edited.
— Paramendra Kumar Bhagat (@paramendra) March 25, 2026
Raise money. Do you need help? I feel like you are in a position .... ask, and it will be given.
For the book idea, you have said plenty in your many tweets. As in, you don't have to do interviews or anything. But it would help if there were a book that explained the whole thing in simple terms. Would really help the fundraising and media relations. PR. Recruiting.
— Paramendra Kumar Bhagat (@paramendra) March 25, 2026
The tone of the book will be along these lines.
— Paramendra Kumar Bhagat (@paramendra) March 25, 2026
How Big Is the Universe? https://t.co/83sOKPDDEI
Precigenetics: Building the Eyes AI Needs to Finally Solve Biology
Parmita Mishra, founder and CEO of Precigenetics, has spent years explaining her company’s mission in her own words on X. From detailed threads about why drug discovery is broken to real-time updates on prototypes and hardware decisions, her posts paint a consistent picture: Precigenetics is not another diagnostics device maker or sequencing company. It is a drug-discovery platform that uses live, label-free optical spectroscopy to give artificial intelligence the one thing it has always lacked—real-time eyes on living cells. What Precigenetics IsAt its core, Precigenetics is a microfluidic system integrated with advanced spectroscopy (often drawing on quantum optics) that captures real-time spectral fingerprints of living cells. No antibodies. No fluorescent labels. No killing the cell to extract RNA or DNA. Instead, it reads lipid content, protein conformation, nucleic acid states, metabolic shifts—and, through specialized chromatin imaging, even a “video” of epigenetic changes inside the nucleus—all while the cell remains alive and responding to drugs over time.
Mishra has repeatedly emphasized that this is chemical imaging at the single-cell level, the kind of “molecular microscope” she first dreamed about years earlier. The platform does not take static snapshots; it records dynamic movies of cellular behavior across time. That temporal dimension is deliberate: every drug acts on a living system that evolves second by second, and traditional methods (like perturb-seq) destroy the very movie they are trying to understand. What Precigenetics Does TodayThe company’s decision to remain a drug-discovery platform rather than a hardware or diagnostics seller is explicit and strategic. Mishra has written that it took her four months of deliberation to reject the easier path of selling sensors or clinical devices. Insurance codes, reimbursement battles, and distribution challenges would have diluted focus. Instead, Precigenetics builds the expensive, room-sized, cutting-edge instrumentation that stays at the frontier of research—where every improvement in sensors, throughput, and cellular models compounds into a data flywheel.
That flywheel is already turning. In 2024 the team built PROTO-1, raised pre-seed funding from top investors, secured partnerships (including one with a leading optics university), assembled an advisory board that includes a Nobel laureate, and selected initial disease areas. By early 2025 they had PROTO-2 plans underway and were generating data never seen before—super-resolution images at scales finer than standard confocal microscopy, plus live epigenetic videos.
The immediate output is training data for AI. Mishra describes the system as “giving AI eyes.” Once the model can watch every one of the trillion chemical reactions happening each second inside each of the 40 trillion cells in a human body, it can learn to predict how a compound will perturb that system—without waiting for mouse trials or decade-long clinical failures. What Precigenetics Hopes to DoThe long-term vision is nothing less than rational drug discovery powered by biological superintelligence. Today’s pharma pipeline wastes $2 billion and ten years per drug while seeing 97 % of cancer candidates fail—largely because humanity has never had a comprehensive dataset of live drug-cell interactions.
Alphafold could predict protein structures only because decades of structural biology data already existed; no equivalent database exists for cellular responses. Precigenetics intends to create it.
By feeding AI continuous, label-free, site-specific, sub-clinical data, the company aims to:
Mishra frames this as a moral and scientific imperative: every patient’s data should accelerate understanding so future patients suffer less. The platform is built to scale that understanding exponentially. She has posted that “we are not pretending we know what human biology is… we are simply seeing it. And so is our AI.”
Recent updates show the work continues at full speed—refining photonic spectra, rejecting single-target biosensors in favor of broad molecular-vibration sensing, and planning public data releases or challenges once throughput scales.
In short, Precigenetics is the bridge between optics, microfluidics, and AI that Mishra believes is “the only one remaining” to make disease solvable with compute. From her first 2023 post that sketched the thesis, through prototype milestones and hard strategic choices, the company’s direction has never wavered: see the unseen layers of life in real time, hand that vision to AI, and finally put biology back into medicine—rationally, at scale, and for good.
Parmita Mishra, founder and CEO of Precigenetics, has spent years explaining her company’s mission in her own words on X. From detailed threads about why drug discovery is broken to real-time updates on prototypes and hardware decisions, her posts paint a consistent picture: Precigenetics is not another diagnostics device maker or sequencing company. It is a drug-discovery platform that uses live, label-free optical spectroscopy to give artificial intelligence the one thing it has always lacked—real-time eyes on living cells. What Precigenetics IsAt its core, Precigenetics is a microfluidic system integrated with advanced spectroscopy (often drawing on quantum optics) that captures real-time spectral fingerprints of living cells. No antibodies. No fluorescent labels. No killing the cell to extract RNA or DNA. Instead, it reads lipid content, protein conformation, nucleic acid states, metabolic shifts—and, through specialized chromatin imaging, even a “video” of epigenetic changes inside the nucleus—all while the cell remains alive and responding to drugs over time.
Mishra has repeatedly emphasized that this is chemical imaging at the single-cell level, the kind of “molecular microscope” she first dreamed about years earlier. The platform does not take static snapshots; it records dynamic movies of cellular behavior across time. That temporal dimension is deliberate: every drug acts on a living system that evolves second by second, and traditional methods (like perturb-seq) destroy the very movie they are trying to understand. What Precigenetics Does TodayThe company’s decision to remain a drug-discovery platform rather than a hardware or diagnostics seller is explicit and strategic. Mishra has written that it took her four months of deliberation to reject the easier path of selling sensors or clinical devices. Insurance codes, reimbursement battles, and distribution challenges would have diluted focus. Instead, Precigenetics builds the expensive, room-sized, cutting-edge instrumentation that stays at the frontier of research—where every improvement in sensors, throughput, and cellular models compounds into a data flywheel.
That flywheel is already turning. In 2024 the team built PROTO-1, raised pre-seed funding from top investors, secured partnerships (including one with a leading optics university), assembled an advisory board that includes a Nobel laureate, and selected initial disease areas. By early 2025 they had PROTO-2 plans underway and were generating data never seen before—super-resolution images at scales finer than standard confocal microscopy, plus live epigenetic videos.
The immediate output is training data for AI. Mishra describes the system as “giving AI eyes.” Once the model can watch every one of the trillion chemical reactions happening each second inside each of the 40 trillion cells in a human body, it can learn to predict how a compound will perturb that system—without waiting for mouse trials or decade-long clinical failures. What Precigenetics Hopes to DoThe long-term vision is nothing less than rational drug discovery powered by biological superintelligence. Today’s pharma pipeline wastes $2 billion and ten years per drug while seeing 97 % of cancer candidates fail—largely because humanity has never had a comprehensive dataset of live drug-cell interactions.
Alphafold could predict protein structures only because decades of structural biology data already existed; no equivalent database exists for cellular responses. Precigenetics intends to create it.
By feeding AI continuous, label-free, site-specific, sub-clinical data, the company aims to:
- Predict cellular outcomes before a drug ever reaches a patient.
- Design ideal molecules based on observed responses rather than statistical luck.
- Move beyond “disease” as a late-stage label and instead map the entire progression of complex, epigenetically driven conditions.
- Ultimately make biology as computable as physics—turning the limiting reagent (high-quality live data) into the fuel for curing disease instead of merely treating symptoms.
Recent updates show the work continues at full speed—refining photonic spectra, rejecting single-target biosensors in favor of broad molecular-vibration sensing, and planning public data releases or challenges once throughput scales.
In short, Precigenetics is the bridge between optics, microfluidics, and AI that Mishra believes is “the only one remaining” to make disease solvable with compute. From her first 2023 post that sketched the thesis, through prototype milestones and hard strategic choices, the company’s direction has never wavered: see the unseen layers of life in real time, hand that vision to AI, and finally put biology back into medicine—rationally, at scale, and for good.
Digitizing biology like we digitized intelligence.
— Precigenetics (@precigenetic) September 30, 2025
Link below. pic.twitter.com/t5MNzUfr8E
Parmita Mishra: The Relentless Builder Behind Precigenetics
Parmita Mishra is the founder and CEO of Precigenetics, the company pioneering label-free, live-cell optical spectroscopy to give AI real-time “eyes” on living biology. On X, where she shares unfiltered updates about hardware builds, scientific frustrations, and deeply personal reflections, Mishra emerges as a fiercely determined scientist-entrepreneur shaped by her Indian roots, academic rigor, and an unshakable belief that biology’s biggest problem is that we still cannot truly see it. Roots in India and a Legacy of HealingMishra’s drive traces directly to her parents, both physicians in India who have collectively saved more than 50,000 lives. Her mother, Dr. Smita Mishra, is a pediatric cardiologist who travels the country closing holes in children’s hearts—often for free—and founded an NGO to support underprivileged kids. Mishra has written movingly about her mother’s sacrifices: staying up until 2 or 4 a.m. after long shifts just to spend time with her daughter, teaching her to be a “strong woman” and a fighter. On Women’s Day 2026, Mishra posted a heartfelt tribute, calling her mother “the best fighter ever” and “the smartest woman on earth,” declaring, “I live to make you proud mamma.” Her father’s medical work is equally revered in her posts. This family legacy of service and persistence clearly forged Mishra’s own refusal to accept “impossible” problems in medicine. Academic Foundation: Computational Biology at an Ivy League UniversityAfter growing up in India, Mishra attended an Ivy League university to study computational biology. She published research, delivered talks at MIT, Berkeley, and multiple academic conferences, then took the bold step of starting her own lab. These experiences gave her deep expertise in the computational side of life sciences—but also exposed the field’s critical blind spots. On X she has pushed back hard against critics who question her credentials, posting on Women’s Day: “I went to an Ivy League university to study computational biology and published research. I also spoke at MIT, Berkeley and multiple academic conferences. Then I started my own lab. What have you done?”
That frustration with traditional biology’s limitations—especially the inability to watch living cells respond to drugs in real time—would eventually crystallize into the thesis for Precigenetics.Founding Precigenetics: Betting Everything on a “Delusion”On May 5, 2024, Mishra incorporated Precigenetics with just $1,000 and a loan from a loved one when she had no money of her own. The decision came at great personal cost. In a raw March 2026 thread she revealed, “I gave away everything for Precigenetics. Everything.” Her parents were “rightly not happy,” her ex was “appalled,” and childhood friends urged her to “visit an asylum.” Her response became something of a personal manifesto: “not all crazy people belong in an asylum. some of them bring their delusion into the tangible realms through the sheer act of building persistently.”
One year later the gamble had paid off in measurable milestones. By May 2025 the team had its full custom hardware stack (costing over half a million dollars) shipped. Half a year earlier she had raised a pre-seed round led by 1517 Fund. The company joined the highly competitive MBC BioLabs incubator, added a chief business officer to the advisory board, and closed a partnership with a rare-disease NGO. A single five-minute call with Garry Tan provided crucial reassurance at a low moment. Mishra marks every win publicly, turning the timeline of a scrappy startup into a visible proof of concept. A Woman Founder in a Skeptical WorldMishra is outspoken about the extra obstacles she faces as a woman in deep tech. In response to praise for building as a female founder, she wrote: “people doubt women, people call me crazy, people call me dangerous because i have emotions for my job, and men will NEVER be told what im told… well, all those people are right. i am dangerously unhinged and crazy and a woman, and it is why i will make it happen.” She frames the skepticism as fuel rather than setback, repeatedly tying her persistence to the same fighter spirit her mother instilled. Vision and Personal PhilosophyBeyond the lab and the company, Mishra’s X feed reveals a scientist with sweeping ambitions: curing cancer and disease, building spectrometers on a chip, even dreaming up 3D food printers and whale-human communication devices. She lists “save all beagles” alongside world-changing goals, blending seriousness with playful defiance. At heart she sees Precigenetics as more than hardware or data—it is a life lesson in turning “delusion” into science. As she put it after one year in: “Brilliance is never easy to come around, and Precigenetics is brilliant, and it is brilliant because it does not care for sanity. It cares for science.”
From the operating rooms of her parents in India to the Ivy League lecture halls and now the cleanrooms of her own startup, Parmita Mishra has consistently chosen the harder, more visionary path. Her story on X is not polished corporate PR; it is raw, real-time proof that building the future of biology demands both technical brilliance and the willingness to be called crazy—then proving everyone wrong by delivering the data.
Parmita Mishra is the founder and CEO of Precigenetics, the company pioneering label-free, live-cell optical spectroscopy to give AI real-time “eyes” on living biology. On X, where she shares unfiltered updates about hardware builds, scientific frustrations, and deeply personal reflections, Mishra emerges as a fiercely determined scientist-entrepreneur shaped by her Indian roots, academic rigor, and an unshakable belief that biology’s biggest problem is that we still cannot truly see it. Roots in India and a Legacy of HealingMishra’s drive traces directly to her parents, both physicians in India who have collectively saved more than 50,000 lives. Her mother, Dr. Smita Mishra, is a pediatric cardiologist who travels the country closing holes in children’s hearts—often for free—and founded an NGO to support underprivileged kids. Mishra has written movingly about her mother’s sacrifices: staying up until 2 or 4 a.m. after long shifts just to spend time with her daughter, teaching her to be a “strong woman” and a fighter. On Women’s Day 2026, Mishra posted a heartfelt tribute, calling her mother “the best fighter ever” and “the smartest woman on earth,” declaring, “I live to make you proud mamma.” Her father’s medical work is equally revered in her posts. This family legacy of service and persistence clearly forged Mishra’s own refusal to accept “impossible” problems in medicine. Academic Foundation: Computational Biology at an Ivy League UniversityAfter growing up in India, Mishra attended an Ivy League university to study computational biology. She published research, delivered talks at MIT, Berkeley, and multiple academic conferences, then took the bold step of starting her own lab. These experiences gave her deep expertise in the computational side of life sciences—but also exposed the field’s critical blind spots. On X she has pushed back hard against critics who question her credentials, posting on Women’s Day: “I went to an Ivy League university to study computational biology and published research. I also spoke at MIT, Berkeley and multiple academic conferences. Then I started my own lab. What have you done?”
That frustration with traditional biology’s limitations—especially the inability to watch living cells respond to drugs in real time—would eventually crystallize into the thesis for Precigenetics.Founding Precigenetics: Betting Everything on a “Delusion”On May 5, 2024, Mishra incorporated Precigenetics with just $1,000 and a loan from a loved one when she had no money of her own. The decision came at great personal cost. In a raw March 2026 thread she revealed, “I gave away everything for Precigenetics. Everything.” Her parents were “rightly not happy,” her ex was “appalled,” and childhood friends urged her to “visit an asylum.” Her response became something of a personal manifesto: “not all crazy people belong in an asylum. some of them bring their delusion into the tangible realms through the sheer act of building persistently.”
One year later the gamble had paid off in measurable milestones. By May 2025 the team had its full custom hardware stack (costing over half a million dollars) shipped. Half a year earlier she had raised a pre-seed round led by 1517 Fund. The company joined the highly competitive MBC BioLabs incubator, added a chief business officer to the advisory board, and closed a partnership with a rare-disease NGO. A single five-minute call with Garry Tan provided crucial reassurance at a low moment. Mishra marks every win publicly, turning the timeline of a scrappy startup into a visible proof of concept. A Woman Founder in a Skeptical WorldMishra is outspoken about the extra obstacles she faces as a woman in deep tech. In response to praise for building as a female founder, she wrote: “people doubt women, people call me crazy, people call me dangerous because i have emotions for my job, and men will NEVER be told what im told… well, all those people are right. i am dangerously unhinged and crazy and a woman, and it is why i will make it happen.” She frames the skepticism as fuel rather than setback, repeatedly tying her persistence to the same fighter spirit her mother instilled. Vision and Personal PhilosophyBeyond the lab and the company, Mishra’s X feed reveals a scientist with sweeping ambitions: curing cancer and disease, building spectrometers on a chip, even dreaming up 3D food printers and whale-human communication devices. She lists “save all beagles” alongside world-changing goals, blending seriousness with playful defiance. At heart she sees Precigenetics as more than hardware or data—it is a life lesson in turning “delusion” into science. As she put it after one year in: “Brilliance is never easy to come around, and Precigenetics is brilliant, and it is brilliant because it does not care for sanity. It cares for science.”
From the operating rooms of her parents in India to the Ivy League lecture halls and now the cleanrooms of her own startup, Parmita Mishra has consistently chosen the harder, more visionary path. Her story on X is not polished corporate PR; it is raw, real-time proof that building the future of biology demands both technical brilliance and the willingness to be called crazy—then proving everyone wrong by delivering the data.
🧬 Precigenetics: Digitizing Biology for the Age of AI https://t.co/mdepTEBhtc
— Paramendra Kumar Bhagat (@paramendra) March 25, 2026
Two people that keep showing up in my Twitter timeline more often than anyone else. @elonmusk @parmita
— Paramendra Kumar Bhagat (@paramendra) March 26, 2026
Cc: @DStrachman pic.twitter.com/Nayse68wzx
